Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia.

Crescioli, C; Ferruzzi, P; Caporali, A; Scaltriti, M; Bettuzzi, S; Mancina, R; Gelmini, S; Serio, M; Villari, D; Vannelli, G B; Colli, E; Adorini, L; Maggi, M

Crescioli, C; Ferruzzi, P; Caporali, A; Scaltriti, M; Bettuzzi, S; Mancina, R; Gelmini, S; Serio, M; Villari, D; Vannelli, G B; Colli, E; Adorini, L; Maggi, M.

Affiliation

Crescioli C; Department of Clinical Physiopathology, University of Florence, Florence, Italy.

Eur J Endocrinol ; 150(4): 591-603, 2004 Apr.

Article in En | MEDLINE | ID: mdl-15080791

Subject(s)

Calcitriol/analogs & derivatives; Calcitriol/administration & dosage; Prostate/drug effects; Prostatic Hyperplasia/drug therapy; Animals; Cell Division/drug effects; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Male; Orchiectomy; Prostate/pathology; Prostatic Hyperplasia/pathology; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured/drug effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostate / Prostatic Hyperplasia / Calcitriol Type of study: Clinical_trials Limits: Animals / Humans / Male Language: En Journal: Eur J Endocrinol Journal subject: ENDOCRINOLOGIA Year: 2004 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links